Patents by Inventor Franz J Weiberth

Franz J Weiberth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200383982
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Application
    Filed: December 23, 2019
    Publication date: December 10, 2020
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Publication number: 20190262338
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related to macular degeneration (AMD).
    Type: Application
    Filed: September 20, 2018
    Publication date: August 29, 2019
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Publication number: 20190000845
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Application
    Filed: February 23, 2018
    Publication date: January 3, 2019
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Publication number: 20170231990
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Application
    Filed: September 7, 2016
    Publication date: August 17, 2017
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Patent number: 9469627
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 18, 2016
    Assignee: Sanofi
    Inventors: Christopher L. Vandeusen, Franz J. Weiberth, Harpal S. Gill, George Lee, Andrea Hillegass
  • Publication number: 20120190695
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Application
    Filed: April 4, 2012
    Publication date: July 26, 2012
    Applicant: SANOFI
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Publication number: 20120010409
    Abstract: An improved synthesis method for making diazaindoles using a Chichibabin cyclization is disclosed. In particular, this method is useful for making the compound of Formula I.
    Type: Application
    Filed: March 18, 2010
    Publication date: January 12, 2012
    Applicant: SANOFI
    Inventors: George E. Lee, Frederick L. Shrimp, II, Franz J. Weiberth
  • Publication number: 20110021777
    Abstract: An improved chemical synthesis for intermediates of compounds having useful biological activity is disclosed, where the use of PBr3 is employed as a reagent for a selective ring opening of cyclopropylcarbinols to give bromopropylidene products which are highly selectively the E isomer.
    Type: Application
    Filed: May 26, 2010
    Publication date: January 27, 2011
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventor: Franz J. WEIBERTH
  • Patent number: 7550469
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: June 23, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: James A Hendrix, Joseph T Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G Jurcak, Harpal Gill, Franz J Weiberth, Thaddeus Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
  • Publication number: 20040030137
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: February 19, 2002
    Publication date: February 12, 2004
    Inventors: James A. Hendrix, Joseph T. Strupczewski, Kenneth J. Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G. Jurcak, Harpal Gill, Franz J. Weiberth, Thaddeus R. Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
  • Patent number: 5455354
    Abstract: This invention relates to a process for the preparation of a product of the formula ##STR1## wherein R, R.sup.1, R.sup.2, X and m are defined within which process comprises(a) contacting a compound of Formula II ##STR2## wherein R.sup.3 is loweralkyl, with a reagent selective from the group consisting of aluminum chloride, hydrobromic acid and boron tribromide followed by tartaric acid to afford a compound of Formula III ##STR3## wherein R, X and m are as defined above; (b) contacting the reaction mixture containing compound of Formula IV ##STR4## wherein R.sup.4 is hydrogen or loweralkyl in the presence of a carboxylic acid of the formulaR.sup.5 COOHwherein R.sup.5 is loweralkyl to afford a compound of formula V ##STR5## wherein R, R.sup.4, X and m are as above; contacting the reaction mixture containing the compound of Formula V obtained in step(b) with a compound of the formulaR.sup.1 R.sup.2 NHwherein R.sup.1 and R.sup.2 are as above; and isolating the product of Formula I.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: October 3, 1995
    Assignee: Hoechst-Roussel Pharmaceuticals Incorporated
    Inventors: George S. K. Wong, Thomas B. K. Lee, Franz J. Weiberth
  • Patent number: 5302721
    Abstract: This application relates to a new process for the preparation of a product of the formula ##STR1## wherein R is loweralkyl;R.sup.1 is hydrogen, loweralkyl, lowercycloalkyl, lowercycloalkylloweralkyl, lowerbicycloalkyl, aryl or arylloweralkyl;R.sup.2 is loweralkyl, lowercycloalkyl, lowercycloalkylloweralkyl, lowerbicycloalkyl, aryl or arylloweralkyl; orR.sup.1 and R.sup.2 taken together with the nitrogen atom to which they are attached from a 3,4-dihydro-2H(1H)-isoquinoline group;X is loweralkyl, loweralkoxy, halogen or trifluoromethyl; andm is 0, 1 or 2;which process comprises(a) contacting a compound of formula II ##STR2## wherein R, X and m are as defined above and R.sup.3 is loweralkyl, with aluminum chloride followed by tartaric acidto afford a compound of formula III ##STR3## wherein R, X and m are as defined above; (b) contacting the reaction mixture containing the compound of Formula III either(1) with an isocyanate of the formula R.sup.1 NCO and obtaining a product of the formula I wherein R.sup.
    Type: Grant
    Filed: July 21, 1992
    Date of Patent: April 12, 1994
    Assignee: Hoechst-Roussel Pharmaceuticals Incorporated
    Inventors: George S. K. Wong, Thomas B. K. Lee, Franz J. Weiberth